A National Science Foundation grant will support Princeton researchers studying how COVID-19 may be spread by people without symptoms through everyday social interactions involving breathing and speaking.
Catching COVID-19 isn’t all-or-nothing, says virus researcher Caroline Bartman in the latest episode of Princeton University’s “We Roar” podcast. Instead, it’s more like a poison: while a tiny amount of most toxins might just make you queasy, a heaping spoonful would be deadly. And like lead poisoning from old pipes, the dose accumulates over time.
Three research endeavors aimed at fundamental challenges in health, information technology and water conservation have been selected for funding through the Eric and Wendy Schmidt Transformative Technology Fund.
In just six weeks, from March 19 to May 1, an international team of physicists and engineers led by Princeton’s Cristian Galbiati brought a ventilator from concept to FDA approval.
The U.S. Food and Drug Administration announced on Sunday, May 3, that the Mechanical Ventilator Milano (MVM) is safe for use in the United States under the FDA’s Emergency Use Authorization, which helps support public health during a crisis.
With the aim of accelerating solutions to the challenges of the COVID-19 pandemic, Princeton has awarded University funding for seven new faculty-led research initiatives with strong potential for impact.
The funding enables faculty and their teams to address crucial questions in biomedical, health-related and fundamental science, as well as policy, social and economic topics. Projects will receive funding of up to $100,000.
A study published in the journal Nature Microbiology identified factors that the hepatitis B virus uses when establishing long-term infection in the liver. The findings could help lead to treatment strategies for chronic HBV infection, a condition that increases the risk of developing liver cancer and is responsible for almost 900,000 deaths worldwide each year. Continue Reading on the Discovery: Research at Princeton blog →
When corporate partners in the Princeton Catalysis Initiative sat down two years ago with David MacMillan, they presented him with a biological challenge at the heart of potential cancer medicines and other therapeutics: which proteins on a cell’s surface touch each other?
Researchers at Princeton University have revealed the inner workings of a gene repression mechanism in fruit fly embryos, adding insight to the study of human diseases.
Optimeos Life Sciences, a startup founded by two Princeton University faculty members, has reached agreements with six pharmaceutical companies to develop therapeutics using a Princeton-developed drug delivery technology. The collaborations have the potential to improve the effectiveness of medications for the treatment of diseases, ranging from cancer to diabetes.
